Carrilizumab plus GEMOX
Phase 2Small molecule
Carrilizumab plus GEMOX is one of 11 small molecule programs targeting Gallbladder Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Gallbladder Cancer
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Tykerb
NovartisApproved
Gemzar
Johnson & JohnsonPhase 3
Photofrin
PPinnacle Biologics Inc.
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Imfinzi
AstraZenecaPhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Gemzar
GGynecologic Oncology Group
Phase 2
AK112
SSummit Therapeutics
Phase 2
Astplayer
AAstex Pharmaceuticals, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gallbladder Cancer1 trial
A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05919095·37 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carrilizumab plus GEMOX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details